Roula Ghaoui1, Sandra T Cooper1, Monkol Lek2, Kristi Jones1, Alastair Corbett3, Stephen W Reddel3, Merrilee Needham4, Christina Liang5, Leigh B Waddell1, Garth Nicholson6, Gina O'Grady1, Simranpreet Kaur1, Royston Ong7, Mark Davis8, Carolyn M Sue5, Nigel G Laing7, Kathryn N North9, Daniel G MacArthur2, Nigel F Clarke1. 1. Institute for Neuroscience and Muscle Research, Kid's Research Institute, Children's Hospital at Westmead, Sydney, New South Wales, Australia2Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, New South Wales. 2. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston. 3. Department of Neurology, Concord General Repatriation Hospital, Sydney, New South Wales, Australia. 4. Western Australian Neurosciences Research Institute, University of Western Australia, Perth, Western Australia, Australia. 5. Department of Neurology, Royal North Shore Hospital, Sydney, New South Wales, Australia. 6. University of Sydney ANZAC Research Institute and Molecular Medicine Laboratory, Concord Hospital, Sydney, New South Wales, Australia. 7. Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia. 8. Department of Diagnostic Genomics, Pathwest Laboratory Medicine, Perth, Western Australia, Australia. 9. Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Victoria, Australia.
Abstract
IMPORTANCE: To our knowledge, the efficacy of transferring next-generation sequencing from a research setting to neuromuscular clinics has never been evaluated. OBJECTIVE: To translate whole-exome sequencing (WES) to clinical practice for the genetic diagnosis of a large cohort of patients with limb-girdle muscular dystrophy (LGMD) for whom protein-based analyses and targeted Sanger sequencing failed to identify the genetic cause of their disorder. DESIGN, SETTING, AND PARTICIPANTS: We performed WES on 60 families with LGMDs (100 exomes). Data analysis was performed between January 6 and December 19, 2014, using the xBrowse bioinformatics interface (Broad Institute). Patients with LGMD were ascertained retrospectively through the Institute for Neuroscience and Muscle Research Biospecimen Bank between 2006 and 2014. Enrolled patients had been extensively investigated via protein studies and candidate gene sequencing and remained undiagnosed. Patients presented with more than 2 years of muscle weakness and with dystrophic or myopathic changes present in muscle biopsy specimens. MAIN OUTCOMES AND MEASURES: The diagnostic rate of LGMD in Australia and the relative frequencies of the different LGMD subtypes. Our central goals were to improve the genetic diagnosis of LGMD, investigate whether the WES platform provides adequate coverage of known LGMD-related genes, and identify new LGMD-related genes. RESULTS: With WES, we identified likely pathogenic mutations in known myopathy genes for 27 of 60 families. Twelve families had mutations in known LGMD-related genes. However, 15 families had variants in disease-related genes not typically associated with LGMD, highlighting the clinical overlap between LGMD and other myopathies. Common causes of phenotypic overlap were due to mutations in congenital muscular dystrophy-related genes (4 families) and collagen myopathy-related genes (4 families). Less common myopathies included metabolic myopathy (2 families), congenital myasthenic syndrome (DOK7), congenital myopathy (ACTA1), tubular aggregate myopathy (STIM1), myofibrillar myopathy (FLNC), and mutation of CHD7, usually associated with the CHARGE syndrome. Inclusion of family members increased the diagnostic efficacy of WES, with a diagnostic rate of 60% for "trios" (an affected proband with both parents) vs 40% for single probands. A follow-up screening of patients whose conditions were undiagnosed on a targeted neuromuscular disease-related gene panel did not improve our diagnostic yield. CONCLUSIONS AND RELEVANCE: With WES, we achieved a diagnostic success rate of 45.0% in our difficult-to-diagnose cohort of patients with LGMD. We expand the clinical phenotypes associated with known myopathy genes, and we stress the importance of accurate clinical examination and histopathological results for interpretation of WES, with many diagnoses requiring follow-up review and ancillary investigations of biopsy specimens or serum samples.
IMPORTANCE: To our knowledge, the efficacy of transferring next-generation sequencing from a research setting to neuromuscular clinics has never been evaluated. OBJECTIVE: To translate whole-exome sequencing (WES) to clinical practice for the genetic diagnosis of a large cohort of patients with limb-girdle muscular dystrophy (LGMD) for whom protein-based analyses and targeted Sanger sequencing failed to identify the genetic cause of their disorder. DESIGN, SETTING, AND PARTICIPANTS: We performed WES on 60 families with LGMDs (100 exomes). Data analysis was performed between January 6 and December 19, 2014, using the xBrowse bioinformatics interface (Broad Institute). Patients with LGMD were ascertained retrospectively through the Institute for Neuroscience and Muscle Research Biospecimen Bank between 2006 and 2014. Enrolled patients had been extensively investigated via protein studies and candidate gene sequencing and remained undiagnosed. Patients presented with more than 2 years of muscle weakness and with dystrophic or myopathic changes present in muscle biopsy specimens. MAIN OUTCOMES AND MEASURES: The diagnostic rate of LGMD in Australia and the relative frequencies of the different LGMD subtypes. Our central goals were to improve the genetic diagnosis of LGMD, investigate whether the WES platform provides adequate coverage of known LGMD-related genes, and identify new LGMD-related genes. RESULTS: With WES, we identified likely pathogenic mutations in known myopathy genes for 27 of 60 families. Twelve families had mutations in known LGMD-related genes. However, 15 families had variants in disease-related genes not typically associated with LGMD, highlighting the clinical overlap between LGMD and other myopathies. Common causes of phenotypic overlap were due to mutations in congenital muscular dystrophy-related genes (4 families) and collagen myopathy-related genes (4 families). Less common myopathies included metabolic myopathy (2 families), congenital myasthenic syndrome (DOK7), congenital myopathy (ACTA1), tubular aggregate myopathy (STIM1), myofibrillar myopathy (FLNC), and mutation of CHD7, usually associated with the CHARGE syndrome. Inclusion of family members increased the diagnostic efficacy of WES, with a diagnostic rate of 60% for "trios" (an affected proband with both parents) vs 40% for single probands. A follow-up screening of patients whose conditions were undiagnosed on a targeted neuromuscular disease-related gene panel did not improve our diagnostic yield. CONCLUSIONS AND RELEVANCE: With WES, we achieved a diagnostic success rate of 45.0% in our difficult-to-diagnose cohort of patients with LGMD. We expand the clinical phenotypes associated with known myopathy genes, and we stress the importance of accurate clinical examination and histopathological results for interpretation of WES, with many diagnoses requiring follow-up review and ancillary investigations of biopsy specimens or serum samples.
Authors: Samantha J Bryen; Himanshu Joshi; Frances J Evesson; Cyrille Girard; Roula Ghaoui; Leigh B Waddell; Alison C Testa; Beryl Cummings; Susan Arbuckle; Nicole Graf; Richard Webster; Daniel G MacArthur; Nigel G Laing; Mark R Davis; Reinhard Lührmann; Sandra T Cooper Journal: Am J Hum Genet Date: 2019-08-22 Impact factor: 11.025
Authors: Gina L O'Grady; Heather A Best; Tamar E Sztal; Vanessa Schartner; Myriam Sanjuan-Vazquez; Sandra Donkervoort; Osorio Abath Neto; Roger Bryan Sutton; Biljana Ilkovski; Norma Beatriz Romero; Tanya Stojkovic; Jahannaz Dastgir; Leigh B Waddell; Anne Boland; Ying Hu; Caitlin Williams; Avnika A Ruparelia; Thierry Maisonobe; Anthony J Peduto; Stephen W Reddel; Monkol Lek; Taru Tukiainen; Beryl B Cummings; Himanshu Joshi; Juliette Nectoux; Susan Brammah; Jean-François Deleuze; Viola Oorschot Ing; Georg Ramm; Didem Ardicli; Kristen J Nowak; Beril Talim; Haluk Topaloglu; Nigel G Laing; Kathryn N North; Daniel G MacArthur; Sylvie Friant; Nigel F Clarke; Robert J Bryson-Richardson; Carsten G Bönnemann; Jocelyn Laporte; Sandra T Cooper Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani Journal: Mol Genet Metab Date: 2017-10-17 Impact factor: 4.797
Authors: Hemakumar M Reddy; Sherifa A Hamed; Monkol Lek; Satomi Mitsuhashi; Elicia Estrella; Michael D Jones; Lane J Mahoney; Anna R Duncan; Kyung-Ah Cho; Daniel G Macarthur; Louis M Kunkel; Peter B Kang Journal: Muscle Nerve Date: 2016-08-24 Impact factor: 3.217
Authors: Madhurima Saha; Hemakumar M Reddy; Mustafa A Salih; Elicia Estrella; Michael D Jones; Satomi Mitsuhashi; Kyung-Ah Cho; Silveli Suzuki-Hatano; Skylar A Rizzo; Muddathir H Hamad; Maowia M Mukhtar; Ahlam A Hamed; Maha A Elseed; Monkol Lek; Elise Valkanas; Daniel G MacArthur; Louis M Kunkel; Christina A Pacak; Isabelle Draper; Peter B Kang Journal: Physiol Genomics Date: 2018-08-31 Impact factor: 3.107